aTyr Pharma Inc. (LIFE) |
|
12.79 1.27 (11.02%)
|
09-23 14:50 |
|
Open: |
11.71 |
Pre. Close: |
11.52 |
|
High:
|
12.89 |
Low:
|
11.6 |
|
Volume:
|
5,626,624 |
Market Cap:
|
336M |
|
|
|
|
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. The company is headquartered in San Diego, California and currently employs 42 full-time employees. The firm is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The firm focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The firm is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The firm is investigating Resolaris in patients with LGMD2B. The firm is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The firm has not generated any revenues. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.349 - 12.408 |
12.408 - 12.463 |
|
Low:
|
10.221 - 10.279 |
10.279 - 10.333 |
|
Close:
|
11.902 - 12.005 |
12.005 - 12.103 |
|
Technical analysis |
as of: 2021-09-23 2:42:36 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 15.15 One year: 17.69 |
| Support: |
Support1: 7.74 Support2: 4.50 |
| Resistance: |
Resistance1: 12.97 Resistance2: 15.15 |
| Pivot: |
7.95  |
| Moving Average: |
MA(5): 10.86 MA(20): 7.30
MA(100): 5.05 MA(250): 4.50 |
| MACD: |
MACD(12,26): 1.64 Signal(9): 1.10 |
| Stochastic oscillator: |
%K(14,3): 78.01 %D(3): 72.08 |
| RSI: |
RSI(14): 81.70 |
| 52-week: |
High: 12.97 Low: 2.93 Change(%): 199.2 |
| Average Vol(K): |
3-Month: 1030056 10-Days: 3047754 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.LIFE has closed below upper band by 13.9%. Bollinger Bands are 684% wider than normal. The large width of the bands suggest high volatility as compared to LIFE's normal range. The bands have been in this wide range for 7 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 23 Sep 2021
Is aTyr Pharma Inc (LIFE) Stock Worth a Buy Thursday? - InvestorsObserver
Thu, 23 Sep 2021
Thursday 9/23 Insider Buying Report: LIFE, CRDF - Nasdaq
Wed, 22 Sep 2021
Atyr Pharma (LIFE) falls 4.08% on Moderate Volume September 22 - Equities.com
Wed, 22 Sep 2021
Premarket Mover: aTyr Pharma Inc (LIFE) Down 2.25% - InvestorsObserver
Tue, 21 Sep 2021
aTyr Pharma Inc (LIFE) has gained 3.42% Tuesday In Premarket Trading - InvestorsObserver
Mon, 20 Sep 2021
aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters' Option to - GlobeNewswire
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
16 |
| Shares Float (M) |
14 |
|
% Held by Insiders
|
3.75 |
|
% Held by Institutions
|
49.20 |
|
Shares Short (K)
|
547 |
|
Shares Short P. Month (K)
|
620 |
Stock Financials |
|
EPS
|
-2.290 |
|
EPS Est This Year
|
-2.180 |
|
EPS Est Next Year
|
-1.820 |
|
Book Value (p.s.)
|
3.100 |
|
Profit Margin
|
|
|
Operating Margin
|
-1322.08 |
|
Return on Assets (ttm)
|
-37.7 |
|
Return on Equity (ttm)
|
-75.8 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-0.426 |
|
Sales Per Share
|
0.137 |
|
EBITDA (p.s.)
|
-1.781 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-24 |
|
Levered Free Cash Flow (M)
|
-13 |
Stock Valuations |
|
PE Ratio
|
-5.03 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.72 |
|
Price to Sales
|
84.10 |
|
Price to Cash Flow
|
-7.56 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2019-06-30 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
